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COMMENTARY Open Access
Commentary: considerations for using the
‘Trials within Cohorts’ design in a clinical
trial of an investigational medicinal product
Anna C. Bibby1,2*, David J. Torgerson3, Samantha Leach4, Helen Lewis-White4 and Nick A. Maskell1,2
Abstract
Background: The ‘trials within cohorts’ (TwiC) design is a pragmatic approach to randomised trials in which trial
participants are randomly selected from an existing cohort. The design has multiple potential benefits, including
the option of conducting multiple trials within the same cohort.
Main text: To date, the TwiC design methodology been used in numerous clinical settings but has never been
applied to a clinical trial of an investigational medicinal product (CTIMP). We have recently secured the necessary
approvals to undertake the first CTIMP using the TwiC design. In this paper, we describe some of the considerations
and modifications required to ensure such a trial is compliant with Good Clinical Practice and international clinical
trials regulations.
We advocate using a two-stage consent process and using the consent stages to explicitly differentiate between
trial participants and cohort participants who are providing control data. This distinction ensured compliance but
had consequences with respect to costings, recruitment and the trial assessment schedule.
Conclusion: We have demonstrated that it is possible to secure ethical and regulatory approval for a CTIMP TwiC.
By including certain considerations at the trial design stage, we believe this pragmatic and efficient methodology
could be utilised in other CTIMPs in future.
Keywords: Cohort multiple randomised controlled trials, Trials within cohorts, Clinical trial of an investigational
medicinal product, Two-stage consent
Background
The trials within cohorts (TwiC) methodology, also
known as the cohort multiple randomised controlled
trial (cmRCT) design, is a pragmatic approach to rando-
mised trials [1]. The method uses an existing cohort to
identify eligible trial participants, a proportion of whom
are then randomly selected to be offered the trial interven-
tion. These participants are invited to discuss the inter-
vention and, if they agree, provide consent to receive it,
while participants who are eligible but not selected for the
trial continue cohort follow-up. Non-selected participants
are not informed about the intervention and do not
provide further consent; however, their data are compared
with that of trial participants and in this way they consti-
tute a ‘control’ group (Fig. 1).
The TwiC design has many potential benefits, includ-
ing efficient recruitment, reduction of cross-over,
disappointment bias and attrition in the control group,
and the potential to undertake multiple trials within the
same cohort [1–3]. Additionally, TwiCs replicate real-life
clinical care, where patients are told about interventions
only when they are going to receive them and not if they
are not. In this way, the methodology is highly pragmatic
and can provide useful information on the effectiveness
of interventions [1, 2, 4]. TwiCs may offer a solution to
some of the recognised issues encountered with standard
randomised clinical trials (RCTs), specifically external
validity and efficiency [2, 5]. However, there has been
some unease regarding the ethics of TwiCs, particularly
with respect to informed consent, and diligence is
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required when designing a TwiC to ensure that consent
processes are comprehensive yet proportionate [2, 6–9].
Since its initial description in 2010, the TwiC design has
been used internationally in areas as diverse as public health,
oncology, mental health and chronic disease [10–15]. To
date, however, the methodology has never been used in a
clinical trial of an investigational medicinal product
(CTIMP). For safety reasons, CTIMPs are subject to more
stringent regulations and governance than other research
[16–20]; in order for a CTIMP TwiC to comply with these
regulations, certain considerations are necessary.
Our research group has designed the first CTIMP
TwiC in the world. The trial of intra-pleural bacterial
immunotherapy in mesothelioma (‘TILT’) is a dual-
centre feasibility TwiC (EudraCT no. 2016-004727-23).
TILT has received Clinical Trials Authorisation (CTA)
from the UK Medicines and Healthcare Regulatory
Authority (MHRA) and has been approved by the local
Research Ethics Committee (REC) and the UK Health
Research Authority (HRA). Recruitment is scheduled to
begin shortly. A summary of TILT, including the trial
flow chart, is shown in Additional file 1. We wish to
share our experiences of setting up TILT, for the benefit
of fellow researchers planning CTIMP TwiCs.
Main text
Trials suitable for the TwiC design
As a highly pragmatic methodology, TwiCs can provide
valuable information regarding the real-life utility and
effectiveness of interventions, including investigational
medicinal products. However, the methodology is less
suitable for explanatory trials aiming to evaluate whether
an intervention has an effect under ideal (and therefore
tightly controlled) conditions. Since TwiCs rely on the
use of standard care as the comparator arm, placebo-
controlled trials are not possible. Trials that entail
additional interventions in the control arm, beyond the
remit of usual care, are also incompatible with the TwiC
design, as these would require specific consent for those
procedures from control participants, thus undermining
one of the key tenets of TwiCs. Finally, TwiCs were de-
signed to provide a ‘patient-centred’ consent process in
which every participant is informed about, and gives
consent for, the precise activities and interventions that
they will undergo. Participant blinding, therefore, is not
part of the design. In combination, these factors mean
that, in their current format, TwiCs are not appropriate
for use in early-phase CTIMPs and drug efficacy studies.
Clinical trials regulations
Clinical research involving pharmaceutical products is
guided by the International Committee for Harmonisation
of Technical Requirements for Pharmaceuticals for Human
Use (ICH) Statement on Good Clinical Practice (GCP) [21].
This document provides an international standard for
ethical and scientific quality in research involving human
participants, based on the principles set out in the Declar-
ation of Helsinki. In the EU, this guidance has been
transcribed into law in the form of European Directive
2001/20/EC, also known as the EU Clinical Trials Directive.
Similar legislation has been produced by the Food & Drug
Administration (FDA) in the USA [19] and other regulatory
authorities in other countries. It is a legal requirement that
all CTIMPs conducted in these countries adhere to the
relevant regulations.
Consent in TwiCs
The primary purpose of clinical trials legislation is to
protect the safety, wellbeing and rights of trial partici-
pants. A fundamental component of this is informed
consent, whereby research participants are given infor-
mation about all research procedures, including any
Fig. 1 Schematic representation of the TwiC design
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potential risks associated with those activities. Only once
they have had time to consider this information will the
participants be in a position to make an autonomous, in-
formed decision regarding participation in the research.
In the context of randomised trials in participants who
have capacity, the process of randomisation is a research
activity and should only occur once the participant has
consented to take part in the trial. Although ‘pre-ran-
domisation’ has been used historically, notably as part of
the Zelen design, it was generally considered unethical,
with significant potential to damage the doctor–partici-
pant relationship [22–24]. Initially concerns were voiced
that the TwiC design entailed pre-randomisation; how-
ever, proposal of a ‘staged consent’ model resolved this
issue [6, 25]. With staged consent, participants provided
initial consent at cohort enrolment that included agree-
ment to undergo random selection for future trials and
for use of their data as control data in the event of non-
selection, without further notification. Participants
selected for the intervention were then asked to provide
second consent, specifically related to the trial interven-
tion [6]. Thus, all participants provided consent for
every research activity they experienced.
We adopted the staged consent method for TILT and,
for additional clarity, used the consent stages to expli-
citly separate research processes into cohort or trial
activities. Thus, screening for future TwiCs, random
selection and provision of control data were designated
cohort activities and covered by the cohort consent
form, while investigational medicinal product (IMP)
administration was a trial activity, covered by the trial
consent form. Extrapolation of this approach meant that,
by definition, trial participants were people who had
signed the trial consent form, while everyone else, in-
cluding controls, were simply participating in the cohort,
albeit a comparative cohort with randomisation element.
Separating participants into trial and cohort popula-
tions in this way removed ambiguity, ensured legality
and, we believe, facilitated the approvals processes. For
monitoring and GCP inspection purposes, we intend to
store a copy of the cohort consent form alongside the
trial consent form in TILT participants’ individual files.
In this way, it will be possible to reconstruct every stage
of the TwiC process, with clear documentation of con-
sent before each stage.
We believe this approach is essential for CTIMP
TwiCs. According to article 4.8.10(c) of ICH GCP, par-
ticipants in trials involving IMPs must be informed
about the IMP and the probability of being assigned to
it [21]. Without staged consent, CTIMP TwiCs fail to
meet this requirement, as control participants are not
informed about the IMP or the probability of being se-
lected to receive it. However, by specifying that controls
are cohort participants and that the trial population
consists exclusively of participants who have signed the
trial consent form (i.e. those who were selected to re-
ceive the intervention and agreed), we ensured that TILT
complied with ICH GCP requirements.
However, while this approach clarified important
elements of CTIMP governance, it generated complexity
in other areas. These complexities are discussed below.
Costings
If funding for the cohort and trial were secured from dif-
ferent sources, care is required to ensure that research
costs are correctly allocated and that funders are satisfied
with how their grant monies are utilised. Even though
control participants are not, strictly speaking, participating
in the trial, the intensity of their follow-up will be in-
creased to match the trial assessment schedule. Since
these data will assist in the analysis of trial outcomes, ra-
ther than being collected for cohort purposes, it seems ap-
propriate to include these costs in the funding application
for the trial, with a clear explanation that it will be used to
cover the cost of controls in the cohort.
Another financial consideration for UK trials relates to
National Institute for Health Research (NIHR) study
support resources for studies included on the Clinical
Research Network (CRN) Portfolio. Commensurate with
the complexity of the research, a higher level of support
is available for randomised trials than for observational
studies. By designating controls as cohort participants
rather than trial participants, we limited the level of
study support that participating NHS hospitals could
receive for these participants (although arguably this is
an appropriate limitation since controls only undergo
cohort activities). This factor should be highlighted when
approaching centres to participate in the trial.
Recruitment
As a tertiary centre involved in multiple research studies,
patients are often referred to our service for consider-
ation of clinical trials. With our standard RCTs, we en-
courage recruitment by publicising our trials at clinical
and academic meetings around the UK, and inviting cli-
nicians to refer willing patients to our centre for review.
In doing so, local clinicians are required to inform their
patients that they may be eligible for a trial and enquire
whether they are willing to travel to one of the trial cen-
tres for further discussion and assessment. However, this
approach was not possible with TILT, as it would have
resulted in patients being made aware of the trial’s exist-
ence before enrolment in the cohort, thus rendering
blinding of future control patients impossible and under-
mining one of the main premises of the TwiC approach.
Another consideration regarding participants from
other centres was that while patients may be willing to
travel a significant distance to be screened for a trial,
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they may be disinclined to repeat the journey if they are
not selected for that trial. Consequently, if they were al-
located to be a cohort-based control in a TwiC, they
may decline ongoing follow-up at the trial centre, caus-
ing differential attrition.
For these reasons, recruitment to TILT was limited to
the catchment area of each study centre. Screening and
enrolment data collected as part of the feasibility out-
comes for TILT will be analysed to determine whether
this impacted on recruitment. It is possible, however,
that the increased recruitment efficiency associated with
the TwiC design may outweigh the effect of reduced
external referrals [1].
Study assessment schedule
CTIMPs assessment schedules are usually more inten-
sive than observational cohorts, which tend to be more
pragmatic [26]. However, to obtain meaningful compari-
son data in a TwiC, follow-up of cohort-based controls,
there is a need to match the trial assessment schedule.
It would be impossible to design a cohort with a visit
schedule that matched all potential future TwiCs. Conse-
quently, we specified in the protocol for the cohort study
that the follow-up regimen was flexible and may be altered
based on clinical or research requirements. This was also
mentioned in the participant information sheet for the co-
hort and discussed when informing potential participants
about the study before enrolment. Thus, the assessment
schedule of cohort participants could be adapted if they
were identified as TwiC controls without violating the co-
hort protocol, without subjecting participants to extra as-
sessment visits that may be considered ‘trial-related’ and,
most importantly, without requiring further consent. In this
way, control participants remained blinded to the existence
of the TwiC, while still providing useful comparison data
under circumstances covered by their original consent.
Even with flexible cohort follow-up, however, if a trial
assessment schedule is particularly demanding, altering
a control’s follow-up to match it may induce curiosity or
anxiety and could lead to inadvertent or explicit
unblinding of controls. Furthermore, it could be seen as
unethical to place excessive research demands on the
control population, particularly in our research setting,
where participants have incurable cancer. For this rea-
son, we designed the TILT assessment schedule to be
simple and pragmatic, while remaining sufficient to
generate relevant outcome data. We also ensured that
the follow-up regimen was similar to routine clinical
care. As such, we felt it was ethical and acceptable to
alter controls’ follow-up to match the TILT schedule.
Data collection
Although the trial team needed to appreciate the com-
plexities of a CTIMP TwiC in order to ensure legality
and compliance, the trial processes had to be as straight-
forward as possible in order to allow the trial to be
successfully executed at multiple centres in busy clinical
settings. We therefore elected to use electronic case-
report forms (eCRFs) for data capture, with a common
database for both cohort and trial. Branching logic was
employed to ensure that the correct data fields appeared
depending on whether the participant was enrolled in
TILT, providing control data or simply undergoing
cohort follow-up. The same programming allowed clear
directions to be provided for individual participants re-
garding the timing of their next study visit, thus redu-
cing confusion and the potential for error. Generation of
secondary identification numbers within the database
allowed easy identification of trial and control partici-
pants for data extraction and monitoring purposes.
Ethics Committee approval and Clinical Trials
Authorisation
Our experience of obtaining the necessary approvals from
the Research Ethics Committee (REC) and Medicines &
Healthcare Products Regulatory Agency (MHRA) was posi-
tive. A team member attended an international symposium
on ethical considerations in TwiCs, at which representatives
from the Health Research Authority (HRA) and MHRA
gave presentations [8]. It was clear, therefore, that both or-
ganisations were familiar with the design and had given
consideration to potential ethical issues. The main concern
of the MHRA was that research participants were aware
that they could withdraw from the study at any point and
that safety monitoring requirements were in place. The
HRA outlined guidance on applying a proportionate ap-
proach to consent. An independent ethics consultant was
also in attendance and emphasised the importance of en-
gaging in dialogue with RECs.
Following this symposium, the research team decided
to submit the ethics applications for the cohort and the
TwiC to the same REC. These submissions were made
in quick succession, in January 2017 and March 2017,
respectively. The same investigator (ACB) attended both
REC meetings. It is our opinion that this approach
facilitated the ethics approval process, as the TwiC de-
sign was discussed in length during the cohort review
process, and consequently the panel were already famil-
iar with the concept when the trial review took place.
There was some discussion during the trial review meet-
ing regarding the fact that control participants were not
informed about the trial and whether this represented a
form of ‘deception’. However, the clear distinction be-
tween trial participants, defined as people who had
signed the trial consent form, and controls who contin-
ued to be defined as cohort participants, helped resolve
this. Cohort controls were not being deceived about any-
thing, since they had been fully informed about the
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potential activities involved in participating in the
cohort, including altered follow-up assessment schedules
and provision of control data to TwiCs.
Following submission of our application for Clinical
Trials Authorisation, the MHRA requested minor
amendments be made to the protocol to ensure no trial-
related activities occurred before written informed trial
consent was provided. In addition, they requested clarity
regarding serious adverse event (AE) monitoring in
control patients in the cohort. As a result, the standard
operating procedure for AE monitoring for the trial was
extended to apply to the cohort as well. It was recog-
nised that this would generate extra work for research
teams, but this was considered acceptable given the
importance of participant safety. It also offered the
additional benefit of allowing capture of late or delayed
AEs that may occur after the trial had finished and
participants returned to follow-up in the cohort.
Conclusion
Our experience setting up the first CTIMP TwiC has
been one of innovation and evolution. However, we have
demonstrated that applying the TwiC methodology to
CTIMPs is both possible and achievable, and that the
necessary approvals can be obtained, governance
requirements fulfilled and multiple sites initiated without
undue difficulty.
We employed the two-stage consent process to expli-
citly separate participants into trial or cohort partici-
pants [6]. This approach ensured compliance with EU
Clinical Trials Legislation and, we believe, facilitated the
approvals process by ensuring our submissions to the re-
search ethics committee and MHRA were clear and
unambiguous.
We have shared our experience of the additional com-
plexities associated with CTIMP TwiCs and hope this
will be of benefit to other researchers contemplating this
methodology. We await with anticipation the results of
TILT, which includes feasibility outcomes and qualitative
interviews exploring the experiences of participants in
both the trial and the cohort.
Additional file
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